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1. Introduction 
    Selenium, an essential micronutrient for humans and animals,1–6 is 
a trace element nutrient that functions as selenocysteine for the 
reduction of antioxidant enzymes such as glutathione peroxidases,7,8 
thioredoxin reductase,9 and thyroid hormone deiodinases.10 The 
entire selenoprotein gene population, designated the selenoproteome, 
has been identified in humans and rodents,11 and numerous 
selenoprotein genes have functions in development and health.12 
Selenoproteins are also involved in different human genetic 
disorders.12 The antioxidant activity of selenium plays a protective 
role in 50 human diseases, including prostate, lung, and 
intestine/colon cancer, immunodeficiency, and heart diseases.13–16 It 
is well known that adenine moiety provides the hydrogen bond with 
a variety of biological molecules and contributes to the diverse 
biological functions such as molecular recognition in DNA 
replication and protein biosynthesis.17 Adenine derivatives 
substituted in position 9 have potent cyclic nucleotide 
phosphodiesterase (PDE) inhibition properties with high selectivity 
toward PDE-4.18 For instance, the 9-(2-fluorobenzyl)-N6-
methyladenine has been found to be used as a potent 
anticonvulsant,19 anxiolytic and sedative properties,20 and was a 
relatively potent PDE-4 inhibitor (IC50-2.0 mM).21 Furthermore, 
initial structure activity relationship (SAR) studies around 9-
substituted adenine derivatives allowed us to identify 9-(2-
fluorobenzyl)-N6-methyl-2-trifluoromethyladenine, as a potent PDE-
4 inhibitor (IC50-0.042 mM), with a high selectivity vs PDE-3.21 
Moreover, 9-(2-fluorobenzyl)-N6-methyl-2-trifluoromethyladenine 
elicited also anti-inflammatory properties,22 and marked dose-
dependent inhibition of arachidonate release from human 
mononuclear cells stimulated with N-formyl-Met-Leu-Phe, a suitable 
model to investigate the in vitro anti-inflammatory activity of PDE-4 
inhibitors.23 In addition, 9-(2-fluorobenzyl)-N6-methyl-2-
trifluoromethyladenine and several 9-substituted adenine derivatives 
elicited a concentration-dependent inhibition of the TNFa release 
from mononuclear cells stimulated with lipopolysaccharide (LPS).23 
To our knowledge, chalcogen-containing derivatives substituted in 
position 9 have not been reported. In this paper, we report the 
synthesis of a series of chalcogen-containing adenine derivatives 
substituted in position 9 and two related X-ray single crystal 
structures. 
   
2. Results and Discussion 
    9-(2-Bromoethyl)adenine (2) was obtained from unprotected 
adenine (1) according to the literature method.24 Starting from 
unprotected adenine (1), selective alkylation with dibromoethane in 
the presence of dry K2CO3 in DMF gave the derivative 2 in 45% 
isolated yield.  2 was applied to the synthesis of many kinds of 
chalcogen-containing molecules as a starting material as shown in 
Scheme 1. Reaction of 2 with 0.5 equiv of sodium selenide or 
sodium telluride in DMF at room temperature for 40 h gave the 
corresponding 9,9'-(selenobis(ethane-2,1-diyl))bis(9H-purin-6-
amine) (3) and 9,9'-(tellurobis(ethane-2,1-diyl))bis(9H-purin-6-
amine) (4) in respective 95% and 68% yields. The reactions can be 
accelerated by warning up the reaction solutions; however, brown 
selenium or dark tellurium being found in the resulting suspension 
resulted in reduced yields. Furthermore, lower yields were obtained 
when the reactions were carried out in ethanol/THF (50/50, v/v),  
DMF seemed to perform much better. The use of an excess of 9-(2-
bromoethyl)adenine also improves yields and conversions. Treating 
a suspension of potassium selenocyanate with 9-(2-
bromoethyl)adenine in dry acetone at 60°C led to the formation of 9-
(2-selenocyanatoethyl)adenine (5) in 93% yield. Reacting 
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diphenyldisulfide or diphenyldiselenide with a excess of NaBH4 in 
dry THF/EtOH at room temperature, followed by addition of 9-(2-
bromoethyl)adenine followed by stirring at  room temperature for 24 
h gave rise to 9-(2-(phenylthio)ethyl)adenine (6) and (9-(2-
(phenylselanyl)ethyl)adenine (7) 95% and 80% yields respectively. It 
is noteworthy that the sulfur starting material proved to be more 
reactive than its selenium analogue.   
   In addition, the reaction of 9-(2-bromoethyl)adenine with an 
equivalent of 1-(naphthalen-2-yl)-2-selenocyanateethanone, which 
was obtained from a modified literature method,25 and NaBH4 in dry 
THF/EtOH gave 2-((2-(6-amino-9H-purin-9-yl)ethyl)selanyl)-1-
(naphthalen-2-yl)ethanone (8) in 99% yield. Similarly, 11-((2-(6-
Amino-9H-purin-9-yl)ethyl)selanyl)undecan-1-ol (9) was formed 
from 11-selenocyanatoundecan-1-ol with 9-(2-bromoethyl) adenine 
under the identical reaction conditions in 99% yield. Both reactions 
are very straightforward. Furthermore, the reaction of 9-(2-
bromoethyl)adenine with one equivalent  of potassium selenocyanate 
in ethanol, followed by the hydrolysis with aqueous solution of 
NaOH produced 2-(6-amino-9H-purin-9-yl)ethyl diselane (10) from 
in 87% yield. 
 
 
 
Scheme 1. Synthesis of a series of new selenium-containing derivatives 2 - 10 of adenine 
 
    The synthesis of 9-(2-((2-bromobenzyl)selanyl)ethyl)adenine (11) 
can be achieved from 9-(2-bromoethyl)adenine by two routes as 
shown in Scheme 2 . Stirring a suspension of 1,2-bis(2-
bromobenzyl)diselane (which was prepared following a literature 
method26) with NaBH4 and 9-(2-bromoethyl)adenine in a dry mixed 
medium of THF/EtOH (1 : 1) at room temperature for 20 h led to the 
formation of  9-(2-((2-bromobenzyl)selanyl)ethyl)adenine (11) in 
86% yield. Alternately, mingling 1-bromo-2-
(selenocyanatomethyl)benzene with NaBH4 and 9-(2-
bromoethyl)adenine in dry THF/EtOH (1 : 1) at room temperature 
for 20 h gave the same product in 61% yield. It is noteworthy that 
1,2-bis(2-bromobenzyl)diselane proved to be more efficient starting 
material than 1-bromo-2-(selenocyanatomethyl)benzene for the 
synthesis of the targeted product with high yield. Both reactions 
resulted in the expected products without noticeable byproduct.   
 
 
 
Scheme 2. Synthesis of 9-(2-((2-bromobenzyl)selanyl)ethyl)-9H-
purin-6-amine 11 
 
Breaking the four-membered ring in Woollins’ reagent with two 
molar equivalents of sodium alkanolates formed the sodium O-alkyl 
phenylphosphonodiselenoates 12 – 14 in high yields,27 the latter 
were stirred with an equivalent of 9-(2-bromoethyl)adenine in dry 
THF overnight at room temperature to generate Se-(2-(6-amino-9H-
purin-9-yl)ethyl) O-alkyl phenylphosphonodiselenoates 15 - 17 in 
69% - 87% yields, respectively, as shown in Scheme 3. To reduce 
the probability of any diselenide byproduct formation, these 
reactions were performed in an inert atmosphere. It is noteworthy 
that neither coupling of two O-alkyl phenylphosphonodiselenoate 
molecules nor decomposed selenium were detected.  
Compounds 3 – 11, 15 – 17 were spectrally characterized by 
multi-nuclear NMR and IR spectroscopy and accurate mass 
measurement. All of new compounds showed the anticipated 
molecular ion peaks [M+H]+ or [M+Na]+ and were confirmed by 
satisfactory accurate mass measurements. Two stereoisomers were 
observed by multinuclear NMR in compound 9. The 77Se NMR 
chemical shifts in compounds 3, 5, 7 – 11 fall within the range from 
121.6 to 297.9 ppm, the highest 77Se NMR chemical shift value is 
one of two isomers in compound 9 with long alkyl chain alcohol 
group, whilst the lowest 77Se NMR chemical shift value is the 
compound 3 with a symmetric conformation in Se atom centre. 
Surprisingly, one of two isomers in compound 9 has very low 77Se 
NMR chemical shift (140.0 ppm). Another sample having high 77Se 
NMR chemical shift value (282.8 ppm) is compound 10, in which 
also adopts a symmetric conformation around the Se-Se bridge. With 
the similar conformation as compound 3, the 125Te NMR chemical 
shift value in compound 4 is 199.3 ppm. The 31P NMR spectra of 15 
– 17 show sharp singlets in the range of 79.3 – 83.6 ppm, flanked by 
two pairs of selenium satellites with 31P-77Se coupling constants in 
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the ranges of 434 – 439 Hz and 825 – 831 Hz, indicating the 
presence of both P-Se single bond and P=Se double bond in these 
three compounds. This was further supported by the 77Se NMR 
spectra which showed two pairs of doublets in the range of 307.8 – 
338.6 ppm and -105.9 – -92.1 ppm with matching 31P-77Se coupling 
constants in compounds 15 – 17. The 1H NMR spectra of 15 – 17 
showed two strong singlets ranging from 7.94 – 8.38 ppm, 
accompanied by singlet peaks in the range of 7.15  – 7.53 ppm for 
the ademine NH2 groups, indicated the presence of adenine ring in 
the molecules. The presence of the adenine rings can further 
confirmed by their special five carbon chemical shift values in the 
13C NMR spectra.  
 
 
 
Scheme 3. Synthesis of Se-(2-(6-amino-9H-purin-9-yl)ethyl) O-alkyl 
phenylphosphonodiselenoates 15 - 17 
 
a 
b 
Figure 1. (a) Single crystal X-ray structure of 1-(n aphthalen-2-yl)-
2-selenocyanatoethanone 16. Selected bond lengths (Å) and angles 
(˚) (esds in parentheses): Se(1)-P(1) 2.253(6), Se(2)-P(1) 2.118(5), 
Se(1)-C(9) 1.936(14), P(1)-C(1) 1.640(2), P(1)-O(1) 1.612(13), 
O(1)-C(7) 1.420(3); P(1)-Se(1)-C(9) 100.1(5), Se(1)-P(1)-O(1) 
103.5(6), Se(2)-P(1)-O(1) 113.2(6), O(1)-P(1)-C(1) 101.8(9), Se(1)-
P(1)-Se(2) 114.9(2), Se(1)-P(1)-C(1) 107.5(8), Se(2)-P(1)-C(1) 
114.6(8), P(1)-O(1)-C(7) 124.5(16), Se(1)-C(9)-C(1) 114.5(8); (b) 
shows the hydrogen bonding of intermomelecule within 16.  
Single crystals of 16 (colorless) and 17 (colorless) obtained from 
diffusion of hexane into dichloromethane solutions of the 
compounds in air at room temperature were investigated by X-ray 
diffraction methods and the structures of two compounds were 
determined.28 The structures of 16 (Figure 1a) and 17 (Figure 2a) 
are in the triclinic space group P-1 though 17 contains two 
independent molecules. The structural conformations have the 
phenyl ring and the adenine ring inclined to one another at 75.85° for 
16 and 55.45° for 17. The P(1)-Se(1)-Se(2) mean planes are nearly 
perpendicular to the Se(1)-C-C mean planes (88.26° for 16 and 
86.35° for 17). The P(1)-Se(1) and P(1)-Se(2) distances  [2.253(6) 
and 2.118(5) Å for 16, 2.246(2) and 2.081(2) Å for 17] are typical P-
Se single bond and P=Se double bond characters, comparable to that 
in the similar structures.29   
 
c 
d 
Figure 2. (c) Single crystal X-ray structure of 1-(n aphthalen-2-yl)-
2-selenocyanatoethanone 17. Selected bond lengths (Å) and angles 
(˚) (esds in parentheses): Se(1)-P(1) 2.246(2), Se(2)-P(1) 2.081(2), 
Se(1)-C(9) 1.938(8), P(1)-C(11) 1.774(8), P(1)-O(1) 1.609(8), O(1)-
C(8) 1.428(11); P(1)-Se(1)-C(1) 98.7(2), Se(1)-P(1)-O(1) 103.6(3), 
Se(2)-P(1)-O(1) 116.8(3), O(1)-P(1)-C(11) 97.9(4), Se(1)-P(1)-Se(2) 
114.14(9), Se(1)-P(1)-C(11) 107.3(3), Se(2)-P(1)-C(11) 115.4(3), 
P(1)-O(1)-C(8) 124.7(6), Se(1)-C(1)-C(2) 114.1(5); (d) shows the 
hydrogen bonding of intermomelecule within 17. 
    In conclusion, a series of new chalcogen-containing derivatives of 
DNA nucleobases having the adenine functionality were successfully 
prepared and characterized. Reaction of 9-(2-bromoethyl) adenine 
with sodium selenide, sodium telluride, potassium selenocyanate, 
diphenyldisulfide/ NaBH4, diphenyldiselenide/ NaBH4, 1-
(naphthalen-2-yl)-2-selenocyanateethanone and 11-
selenocyanatoundecan-1-ol with 9-(2-bromoethyl) adenine resulted 
in the corresponding chalcogen-containing heteroatom compounds in 
good to excellent yields. Furthermore, treating 9-(2-bromoethyl) 
adenine with three Woollins’ reagent derivatives of alcohols led to 
the expected formation of three phosphorus-selenium heteroatom 
compounds in excellent yields. The new chalcogen-containing DNA 
nucleobases derivatives might provide a valuable addition to the 
library of selenium-containing heteroatom compounds known. 
3. Experimental section 
 
3.1. General 
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    Unless otherwise stated, all reactions were carried out under on 
oxygen free nitrogen atmosphere using pre-dried solvents and 
standard Schlenk techniques, subsequent chromatographic and work 
up procedures were performed in air. 1H (270 MHz), 13C (67.9 
MHz), 31P-{1H} (109 MHz) and 77Se-{1H} (51.4 MHz referenced to 
external Me2Se) NMR spectra were recorded at 25 
ºC (unless stated 
otherwise) on a JEOL GSX 270. IR spectra were recorded as KBr 
pellets in the range of 4000-250 cm-1 on a Perkin-Elmer 2000 
FTIR/Raman spectrometer. Mass spectrometry was performed by the 
EPSRC National Mass Spectrometry Service Centre, Swansea and 
the University of St Andrews Mass Spectrometry Service. X-ray 
crystal structures were determined for compounds 16 and 17 at -
148(1) °C on a Rigaku ACTOR-SM, Saturn 724 CCD area detector 
[the St Andrews Automated Robotic Diffractometer 
(STANDARD)]31 with SHINE optic using Mo Ka radiation (k = 
0.71073 A). The data were corrected for Lorentz, polarisation and 
absorption. The data was collected and processed using CrystalClear 
(Rigaku).32 The structures were solved by direct methods33 and 
expanded using Fourier techniques.34 Hydrogen atoms were refined 
using the riding model. All calculations were performed using the 
CrystalStructure35 and SHELXL 97.36 These data can be obtained 
free of charge via www.ccdc.cam.ac.uk/conts/retrieving.html or from 
the Cambridge Crystallographic Data centre, 12 Union Road, 
Cambridge CB2 1EZ, UK; fax (+44) 1223-336-033; e-mail: 
deposit@ccdc.cam.ac.uk.  CCDC 985908-985919 
 
3.2. Synthesis  
 
3.2.1. Synthesis of 9,9'-(Selenobis(ethane-2,1-diyl))bisadenine (3).  
 
    A mixture of sodium selenide (0.127 g, 1.0 mmol) and 9-(2-
bromoethyl)adenine (0.482 g, 2.0 mmol) in 10 mL of dry DMF was 
stirred at room temperature for 40 h. Upon filtering to remove the 
solid the filtrate was washed by water and extracted with 
dichloromethane (3x50 mL). The combined organic layer was dried 
over Na2SO4. After evaporative removal of solvent the crude product 
was purified by column chromatography (silica gel) with 15% 
MeOH in dichloromethane as eluent to give 0.385 g as a peach 
yellow solid in 95% yield. Mp. 193 - 195°C. Selected IR (KBr, cm-
1): 1680(s), 1655(s), 1602(s), 1574(m), 1485(s), 1417(s), 1328(s), 
1308(s), 1252(m), 1224(m), 1074(m), 796(m), 650(s). 1H NMR 
(DMF-d7, δ), 8.23 (s, 2H, adenine-H), 8.22 (s, 2H, adenine-H), 7.35 
(s, 4H, NH2), 4.53 (t, J(H,H) = 6.9 Hz, 4H, CH2), 3.18 (t, J(H,H) = 
6.9 Hz, 4H, CH2) ppm. 
13C NMR (DMF-d7, δ), 156.6 (adenine-C), 
152.9 (adenine-C), 150.1 (adenine-C), 141.1 (adenine-C), 119.5 
(adenine-C), 43.7 (CH2), 22.5 (CH2) ppm. 
77Se NMR (DMF-d7, δ), 
121.6 ppm. Mass spectrum [CI+, m/z]: 405 [M+H]+. Accurate mass 
measurement [CI+, m/z]: 405.0799 [M+H]+, calculated mass for 
C14H17N10Se: 405.0797. 
3.2.2. Synthesis of     9,9'-(Tellurobis(ethane-2,1-diyl))bisadenine 
(4). 
 
    A suspension of sodium telluride (0.176 g, 1.0 mmol) and 9-(2-
bromoethyl)adenine (0.482 g, 2.0 mmol) in 10 mL of dry DMF was 
stirred at room temperature for 40 h. Upon filtering to remove the 
solid the filtrate was washed by water and extracted with 
dichloromethane (3x50 mL). The combined organic layer was dried 
over Na2SO4. After evaporative removal of solvent the crude product 
was purified by column chromatography (silica gel) with 15% 
MeOH in dichloromethane as eluent to give 0.310 g as a mustard 
yellow solid in 68% yield. Mp. 196 - 198°C. Selected IR (KBr, cm-
1): 1654(s), 1598(s), 1573(m), 1482(s), 1414(s), 1331(s), 1308(s), 
1247(s), 1072(m), 1008(m), 796(m), 724(m), 645(s). 1H NMR 
(DMF-d7, δ), 8.22 (s, 2H, adenine-H), 8.20 (s, 2H, adenine-H), 7.32 
(s, 4H, NH2), 4.59 (t, J(H,H) = 6.9 Hz, 4H, CH2), 3.21(t, J(H,H) = 
6.9 Hz, 4H, CH2) ppm. 
13C NMR (DMF-d7, δ), 156.6 (adenine-C), 
152.9 (adenine-C), 150.0 (adenine-C), 140.8 (adenine-C), 119.5 
(adenine-C), 45.7(CH2), 1.9(CH2) ppm. 
125Te NMR (DMF-d7, δ), 
199.3 ppm. Mass spectrum [CI+, m/z]: 455 [M+H]+. Accurate mass 
measurement [CI+, m/z]: 455.0681 [M+H]+, calculated mass for 
C14H17N10Te: 455.0695. 
 
 
3.2.3. Synthesis of 9-(2-Selenocyanatoethyl)adenine (5). 
 
    A suspension of potassium selenocyanate (0.145 g, 1.0 mmol) in 
30 mL of dry acetone was heated to 60°C, and 9-(2-
bromoethyl)adenine (0.241 g, 1.0 mmol) in 5 mL of dry acetone was 
slowly added dropwise. The resulting mixture was stirrred at 60 °C 
for another 7 h. Upon cooling to room temperature the mixture was 
hydrolysed (10 mL water) and extracted with diethyl ether (2 x 30 
mL). The ethereal layers were combined and dried over MgSO4 
overnight. The solvent was evaporated in vacuo and the residue was 
purified by silica gel column (dichloromethane as eluent) to give 
0.250 g as a pale purple solid in 93% yield. Mp. 210 - 212°C. 
Selected IR (KBr, cm-1): 1675(s), 1645(m), 1607(s), 1573(m), 
1478(m), 1420(m), 1331(m), 1306(m), 1235(m), 1072(m), 1016(m), 
670(m), 599(m), 540(m), 504(m). 1H NMR (DMF-d7, δ), 8.25 (s, 1H, 
adenine-H), 8.22 (s, 1H, adenine-H), 7.33 (s, 2H, NH2), 4.74 (t, 
J(H,H) = 6.6 Hz, 2H, NCH2), 3.73 (t, J(H,H) = 6.6 Hz, 2H, SeCH2) 
ppm. 13C NMR (DMF-d7, δ), 156.6 (adenine-C), 152.8 (adenine-C), 
150.2 (adenine-C), 141.1 (adenine-C), 119.5 (adenine-C), 103.4 
(C≡N), 44.2 (NCH2), 29.3 (SeCH2) ppm. 
77Se NMR (DMF-d7, δ), 
197.1 ppm. Mass spectrum [CI+, m/z]: 269 [M+H]+. Accurate mass 
measurement [CI+, m/z]: 269.0046 [M+H]+, calculated mass for 
C8H8N6SeH: 269.0048. 
 
3.2.4. Synthesis of 9-(2-(Phenylthio)ethyl)adenine (6). 
 
    A suspension of diphenyldisulfide (0.107 g, 0.5 mmol) and NaBH4 
(0.041 g, 1.1 mmol) in 30 mL of dry THF and 5 mL of dry EtOH 
was stirred at room temperature until a pale yellow solution was 
formed, then 9-(2-bromoethyl)adenine (0.241 g, 1.0 mmol) was 
added. The mixture was stirred at room temperature for 24 h. Upon 
evaporating to remove solvent the residue was purified by silica gel 
column (1 : 4 methanol/dichloromethane as eluent) to give 0.256 g as 
a white solid in 95% yield. Mp. 150 - 152°C. Selected IR (KBr, cm-
1): 1683(vs), 1607(vs), 1574(s), 1477(s), 1418(s), 1331(m), 1302(s), 
1239(m), 1071(m), 1020(m), 881(m), 795(m), 747(s), 692(s). 1H 
NMR (DMF-d7, δ), 8.27 (s, 1H, adenine-H), 8.24 (s, 1H, adenine-H), 
7.48 (d, J(H,H) = 8.0 Hz, 1H, Ar-H), 7.41 (d, J(H,H) = 8.0 Hz, 1H, 
Ar-H), 7.35 (s, 2H, NH2), 7.26-7.21 (m, 2H, Ar-H), 4.71 (t, J(H,H) = 
6.9 Hz, 2H, NCH2),  4.05 (t, J(H,H) = 6.9 Hz, 2H, SCH2), 3.59 (s, 
2H, SCH2) ppm. 
13C NMR (DMF-d7, δ), 156.6 (adenine-C), 153.0 
(adenine-C), 150.2 (adenine-C), 141.3 (adenine-C), 135.3 (Ar-C), 
129.3 (Ar-C), 129.0 (Ar-C), 126.4 (Ar-C), 119.5 (adenine-C), 45.3 
(NCH2), 31.4 (SeCH2) ppm. Mass spectrum [CI
+, m/z]: 272 [M+H]+. 
Accurate mass measurement [CI+, m/z]: 272.0962 [M+H]+, 
calculated mass for C13H13N5SH: 272.0964. 
 
3.2.5. Synthesis of (9-(2-(Phenylselanyl)ethyl)adenine (7). 
 
A suspension of diphenyldiselenide (0.156 g, 0.5 mmol) and 
NaBH4 (0.041 g, 1.1 mmol) in 30 mL of dry THF and 5 mL of dry 
EtOH was stirred at room temperature until a pale yellow solution 
was formed, then 9-(2-bromoethyl)adenine (0.241 g, 1.0 mmol) was 
added. The mixture was stirred at room temperature for 24 h. Upon 
evaporating to remove solvent the residue was purified by silica gel 
column (1 : 4 methanol/dichloromethane as eluent) to give 0.256 g as 
a white solid in 80% yield. Mp. 149 - 150°C. Selected IR (KBr, cm-
1): 1677(s), 1643(m), 1602(vs), 1575(m), 1478(s), 1417(s), 1329(m), 
1305(s), 1252(m), 1229(m), 1071(m), 1-19(m), 741(m), 691(m). 1H 
NMR (DMF-d7, δ), 8.26 (s, 1H, adenine-H), 8.24 (s, 1H, adenine-H), 
7.63 (d, J(H,H) = 8.0 Hz, 1H, Ar-H), 7.55 (d, J(H,H) = 8.0 Hz, 1H, 
Ar-H), 7.36 (s, 2H, NH2),  7.32-7.17 (m, 2H, Ar-H), 4.70 (t, J(H,H) 
= 6.9 Hz, 2H, NCH2),  4.04 (t, J(H,H) = 6.9 Hz, 2H, SeCH2), 3.98 (s, 
2H, SeCH2) ppm. 
13C NMR (DMF-d7, δ), 156.7 (adenine-C), 152.9 
(adenine-C), 150.1 (adenine-C), 141.3 (adenine-C), 141.1 (Ar-C), 
132.1 (Ar-C), 129.5 (Ar-C), 127.1 (Ar-C), 119.5 (adenine-C), 45.2 
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(NCH2), 31.4 (SeCH2) ppm. 
77Se NMR (DMF-d7, δ), 267.7 ppm. 
Mass spectrum [CI+, m/z]: 320 [M+H]+. Accurate mass measurement 
[CI+, m/z]: 320.0408 [M+H]+, calculated mass for C13H13N5SeH: 
320.0409. 
 
3.2.6. Synthesis of 2-((2-(6-Amino-9H-purin-9-yl)ethyl)selanyl)-1-
(naphthalen-2-yl)ethanone (8). 
 
    A suspension of potassium selenocyanate (1.50 g, 10.3 mmol) in 
30 mL of dry acetone was heated to 60 °C, and 2-bromo-1-
(naphthalen-2-yl)ethanone (2.125 g, 8.57 mmol) in 10 mL of acetone 
was slowly added dropwise. The resulting mixture was stirred at 
60 °C for another 5 h. Upon cooling to room temperature the mixture 
was hydrolysed (10 mL water) and extracted ether (2 x 30 mL). The 
ethereal layers were combined and dried over MgSO4 overnight. The 
solvent was evaporated in vacuo and the residue was purified by 
silica gel column (dichloromethane as eluent) to give 2.74 g as a pale 
yellow solid in 99% yield. Mp. 100 - 102°C. Selected IR (KBr, cm-
1): 2151(m), 1656(s), 1624(m), 1468(m), 1383(m), 1356(m), 
1299(m), 1177(s), 1123(m), 996(m), 941(m), 850(m), 821(s), 
744(m), 586(m), 474(s). 1H NMR (CD2Cl2, δ), 8.43 (s, 1H, Nap-H), 
7.96-7.88 (m, 4H, Nap-H), 7.70-7.59 (m, 2H, Nap-H), 5.00 (s, 2H, 
SeCH2) ppm. 
13C NMR (CD2Cl2, δ), 193.3 (C=O), 136.2 (Nap-C), 
132.3 (Nap-C), 131.3 (Nap-C), 131.2 (Nap-C), 129.8 (Nap-C), 129.6 
(Nap-C), 129.1 (Nap-C), 128.0 (Nap-C), 127.4 (Nap-C), 123.4 (Nap-
C), 102.0 (C≡N), 39.1 (Se-C) ppm. 77Se NMR (CD2Cl2, δ), 155.7 
ppm. Mass spectrum [CI+, m/z]: 293 [M+NH4]
+. Accurate mass 
measurement [CI+, m/z]: 293.0191 [M+NH4]
+, calculated mass for 
C13H9NOSeNH4: 293.188. 
    A mixture of 1-(naphthalen-2-yl)-2-selenocyanateethanone (0.275 
g, 1.0 mmol) and NaBH4 (0.041 g, 1.1 mmol) in 30 mL of dry THF 
and 5 mL of dry EtOH was stirred at room temperature until a pale 
yellow solution was formed, then 9-(2-bromoethyl)adenine (0.241 g, 
1.0 mmol) was added. The mixture was stirred at room temperature 
for 20 h. Upon evaporating to remove solvent the residue was 
purified by silica gel column (1 : 4 methanol/dichloromethane as 
eluent) to give 0.350 g as a pal purple solid in 85% yield. Mp. 178 - 
180°C. Selected IR (KBr, cm-1): 1672(vs), 1600(vs), 1575(s), 
1478(m), 1418(m), 1327(m), 1306(s), 1228(m), 1070(m), 1011(m), 
662(s), 598(m), 542(m). 1H NMR (DMF-d7, δ), 8.73 (s, 1H, Nap-H), 
8.26 (s, 1H, adenine-H), 8.24 (s, 1H, adenine-H), 8.05-8.03 (m, 4H, 
Nap-H), 7.70-7.61 (m, 2H, Nap-H), 7.38 (s, 2H, NH2), 3.58 (s, 2H, 
SeCH2), 2.92 (t, J(H,H) = 6.1 Hz, 2H, NCH2), 2.75 (t, J(H,H) = 6.1 
Hz, 2H, SeCH2), ppm. 
13C NMR (CD2Cl2, δ), 193.2 (C=O), 162.7 
(adenine-C), 162.2 (adenine-C), 161.8 (adenine-C), 156.6 (adenine-
C), 152.9 (adenine-C), 141.6 (Nap-C), 141.3 (Nap-C), 130.6 (Nap-
C), 129.8 (Nap-C), 128.7 (Nap-C), 128.5 (Nap-C), 127.9 (Nap-C), 
127.1 (Nap-C), 123.7 (Nap-C), 119.5 (Nap-C), 97.6 (C≡N), 66.5 (Se-
C), 45.2 (N-C), 31.3 (Se-C) ppm. 77Se NMR (DMF-d7, δ), 197.2 
ppm. Mass spectrum [CI+, m/z]: 412 [M+H]+. Accurate mass 
measurement [CI+, m/z]: 412.0670 [M+H]+, calculated mass for 
C19H17N5OSeH: 412.0671. 
  
3.2.7. Synthesis of 1-((2-(6-Amino-9H-purin-9-
yl)ethyl)selanyl)undecan-1-ol (9).  
    A mixture of potassium selenocyanate (2.88 g, 20 mmol) in 50 mL 
of dry acetone was heated to 60 °C, and 2-bromo-11undecanol (5.04 
g, 20 mmol) in 20 mL of acetone was added dropwise to the mixture. 
The resulting mixture was stirredat 60 °C for another 5 h. Upon 
cooling to room temperature the mixture was hydrolysed (30 mL 
water) and extracted with diethyl ether (2 x 50 mL). The ethereal 
layers were combined and dried over MgSO4 overnight. The solvent 
was evaporated in vacuo and the residue was purified by silica gel 
column chromatography (dichloromethane as eluent) to give 5.50 g 
as a pale yellow oil in 99% yield. Selected IR (KBr, cm-1): 2927(s), 
2854(s), 2151(m), 1463(m), 1056(m), 722(m), 628(m), 519(w). 1H 
NMR (CD2Cl2, δ), 5.30 (s, 1H, OH), 3.53 (t, J(H,H) = 7.4 Hz, 2H, 
OCH2), 3.02 (t, J(H,H) = 7.4 Hz, 2H, SeCH2), 1.91-1.79 (m, 4H, 
CH2), 1.55-1.28 (m, 14H, CH2) ppm. 
13C NMR (CD2Cl2, δ), 101.7 
(C≡N), 62.7 (OCH2), 34.4 (SeCH2), 32.9 (CH2), 30.9 (CH2), 29.9 
(CH2), 29.6 (CH2), 29.5 (CH2), 29.4 (CH2), 29.1 (CH2), 28.9 (CH2), 
25.8 (CH2) ppm. 
77Se NMR (CD2Cl2, δ), 207.5 ppm. Mass spectrum 
[ES+, m/z]: 300 [M+Na]+. Mass spectrum [CI+, m/z]: 278 [M+H]+. 
Accurate mass measurement [CI+, m/z]: 278.1018 [M+H]+, 
calculated mass for C12H23NOSeH: 278.1018. 
A suspension of 11-selenocyanatoundecan-1-ol (0.277 g, 1.0 
mmol) and NaBH4 (0.041 g, 1.1 mmol) in 30 mL of dry THF and 5 
mL of dry EtOH was stirred at room temperature until a pale yellow 
solution was formed, then 9-(2-bromoethyl)adenine (0.241 g, 1.0 
mmol) was added. The mixture was stirred at room temperature for 
20 h. Upon evaporating to remove solvent the residue was purified 
by silica gel column chromatography (1 : 4 
methanol/dichloromethane as eluent) to give 0.405 g as a white 
cream solid in 98% yield. Mp. 118 - 119°C. Two diastereoisomers 
were found in ca. 2 : 1 intensity ratio. Selected IR (KBr, cm-1): 
1674(m), 1642(m), 1601(s), 1575(m), 1470(s), 1419(m), 1305(s), 
1253(m), 1059(s), 793(m), 716(m). 1H NMR (DMF-d7, δ), 8.24 (s, 
1H, adenine-H), 8.21 (s, 1H, adenine-H), 7.32 (s, 1H, adenine-H), 
7.26 (s, 1H, adenine-H), 6.81 (s, 2H, NH2), 6.80 (s, 2H, NH2), 4.92 
(t, J(H,H) = 6.1 Hz, 2H, NCH2), 4.50 (t, J(H,H) = 6.1 Hz, 2H, 
NCH2), 4.39 (t, J(H,H) = 6.1 Hz, 2H, SeCH2), 4.04 (t, J(H,H) = 6.1 
Hz, 2H, SeCH2), 3.49 (t, J(H,H) = 6.1 Hz, OCH2), 3.11 (t, J(H,H) = 
6.1 Hz, 2H, SeCH2), 2.95 (t, J(H,H) = 6.1 Hz, OCH2), 2.75 (s, 1Hx2, 
OH), 2.58 (t, J(H,H) = 6.1 Hz, 2H, SeCH2), 1.76-1.30 (m, 18Hx2, 
CH2) ppm. 
13C NMR (DMF-d7, δ), 162.2 (adenine-C), 161.8 
(adenine-C), 156.7 (adenine-C), 156.6 (adenine-C), 152.9 (adenine-
C), 152.8 (adenine-C), 141.2 (adenine-C), 141.1 (adenine-C), 119.1 
(adenine-C), 119.0 (adenine-C), 61.6 (OCH2), 45.2 (SeCH2), 44.1 
(SeCH2), 33.2 (CH2), 31.3 (CH2), 30.9 (CH2), 29.9 (CH2), 29.8 
(CH2), 29.7 (CH2), 29.6 (CH2), 29.3 (CH2), 29.1 (CH2), 26.1 (CH2), 
23.5 (CH2), 22.3 (CH2) ppm. 
77Se NMR (DMF-d7, δ), 297.9, 140.0 
ppm. Mass spectrum [CI+, m/z]: 414 [M+H]+. Accurate mass 
measurement [CI+, m/z]: 414.1759 [M+H]+, calculated mass for 
C18H31N5OSeH: 414.1767. 
 
 
3.2.8. Synthesis of 2-(6-Amino-9H-purin-9-yl)ethyl diselane (10). 
 
    To a suspension of 9-(2-bromoethyl)adenine (0.723 g, 3.0 mmol) 
in 50 mL of dry ethanol was added potassium selenocyanate (0.541 
g, 3.75 mmol) at 20°. The mixture was stirred at that temperature for 
4 h. Then, an aqueous solution of NaOH (0.24 g, 6.0 mmol in 10 mL 
of water) was added to the mixture and stirring was continued for 
another 2 h. After extraction with dichloromethane (30 mL x 3) and 
washing with water (20 mL x 3), the organic layer was dried over 
MgSO4. The organic residue was further purified by silica gel 
chromatography (1 : 5 ethyl acetate / dichloromethane as eluent) to 
give 0.420 g as a off-white solid in 87% isolated yield. Mp. 159 - 
161°C. Selected IR (KBr, cm-1): 1688(s), 1648(s), 1603(s), 1570(m), 
1513(m), 1477(m), 1419(m), 1370(m), 1332(m), 1296(s), 1248(m), 
1219(m), 1079(m), 998(m), 970(m), 887(m), 793(m), 712(s), 641(s), 
592(m), 344(m). 1H NMR (DMF-d7, δ), 8.57 (s, 2H, adenine-H), 
8.30 (s, 2H, adenine-H), 7.54 (s, 4H, adenine-NH2), 6.22 (t, J(H,H) = 
6.9 Hz, 4H, NCH2),  5.18 (t, J(H,H) = 6.9 Hz, 2H, SeCH2), 3.67 (s, 
4H, SeCH2) ppm. 
13C NMR (DMF-d7, δ), 162.7 (adenine-C), 156.8 
(adenine-C), 153.6 (adenine-C), 139.0 (adenine-C), 119.9 (adenine-
C), 45.3 (NCH2), 31.4 (SeCH2) ppm. 
77Se NMR (DMF-d7, δ), 282.8 
ppm. Mass spectrum [CI+, m/z]: 485 [M+H]+. Accurate mass 
measurement [CI+, m/z]: 484.9979 [M+H]+, calculated mass for 
C14H16N10SeH: 484.9965. 
 
3.2.9. 9-(2-((2-Bromobenzyl)selanyl)ethyl)adenine (11).  
    Method 1: 1,2-Bis(2-bromobenzyl)diselane was prepared by a 
modified literature method.26 A suspension of 1,2-bis(2-
bromobenzyl)diselane (0.250 g, 0.5 mmol) and NaBH4 (0.041 g, 1.1 
mmol) in 30 mL of dry THF and 5 mL of dry EtOH was stirred at 
room temperature until a pale yellow solution was formed, then 9-(2-
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bromoethyl)adenine (0.241 g, 1.0 mmol) was added. The mixture 
was stirred at room temperature for 20 h. Upon evaporating to 
remove solvent the residue was purified by silica gel column (1 : 4 
methanol/dichloromethane as eluent) to give 0.354 g as an yellowish 
white solid in 86% yield. Method 2: A mixture of 1-bromo-2-
(selenocyanatomethyl)benzene (0.275 g, 1.0 mmol) and NaBH4 
(0.041 g, 1.1 mmol) in 30 mL of dry THF and 5 mL of dry EtOH 
was stirred at room temperature until a pale yellow solution was 
formed, then 9-(2-bromoethyl)adenine (0.241 g, 1.0 mmol) was 
added. The mixture was allowed to stir at room temperature for 20 h. 
Upon evaporating to remove solvent the residue was purified by 
silica gel column (1 : 4 methanol/dichloromethane as eluent) to give 
0.250 g as an yellowish white solid in 61% yield. M.p. 118 - 119°C. 
Selected IR (KBr, cm-1): 1669(s), 1599(vs), 1477(s), 1416(s), 
1325(m), 1306(s), 1230(m), 1069(m), 1021(m), 797(m), 759(m), 
657(m). 1H NMR (DMF-d7, δ), 8.26 (s, 1H, adenine-H), 8.23 (s, 1H, 
adenine-H), 7.65-7.33 (m, 4H, Ar-H), 7.54 (s, 2H, NH2), 4.70 (t, 
J(H,H) = 6.9 Hz, 2H, CH2), 4.05 (t, J(H,H) = 6.9 Hz, 2H, CH2), 3.59 
(s, 2H, CH2) ppm. 
13C NMR (DMF-d7, δ), 162.3 (adenine-C), 161.8 
(adenine-C), 156.6 (adenine-C), 152.8 (adenine-C), 141.3 (Ar-C), 
139.4 (Ar-C), 133.2 (Ar-C), 131.2 (Ar-C), 129.0 (Ar-C), 124.0 (Ar-
C), 119.5 (adenine-C), 45.2 (NCH2), 31.3 (SeCH2), 26.9 (SeCH2) 
ppm. 77Se NMR (DMF-d7, δ), 225.4 ppm. Mass spectrum [CI
+, m/z]: 
409 [M+H]+. Accurate mass measurement [CI+, m/z]: 408.9705 
[M+NH4]
+, calculated mass for C14H14BrN5SeH: 408.9708. 
 
3.2.10. General procedure for the synthesis of Se-(2-(6-amino-
9H-purin-9-yl)ethyl) O-alkyl phenylphosphonodiselenoates 15 - 
17.  
 
Small pieces of sodium (0.046 g, 2.0 mmol) were stirred in alcohol 
(30 mL) at room temperature until fully dissolved. To this solution 
Woollins’ reagent (0.54 g, 1.0 mmol) was added and heated at 60 °C 
for 15 min. The reaction mixture was allowed to cool to room 
temperature and the resulting yellow solution was filtered through a 
small Celite pad. The filtrate was dried under vacuum and 30 mL of 
THF was added. To this solution 9-(2-bromoethyl)adenine (0.2482 g, 
2.0 mmol) was added and the mixture was stirred at room 
temperature overnight. The resultant mixture was filtrated to remove 
solid and the filtration was dried in vacuo, the residue was purified 
by silica gel column (5% methanol/95% DCM) to give the 
corresponding products 15 - 17. 
 
3.2.10.1. Se-(2-(6-Amino-9H-purin-9-yl)ethyl) O-methyl 
phenylphosphonodiselenoate (15).  
 
    0.800 g as greyish white solid in 87% yield. M.p. 123-125°C. 
Selected IR (KBr, cm-1): 3323(s), 3138(s), 1648(s), 1598(s), 
1481(m), 1415(m), 1301(m), 1251(m), 1105(m), 1019(m), 744(m), 
710(m), 687(m), 549(s), 499(s). 1H NMR (DMF-d7, δ), 8.26 (s, 1H, 
adenine-H), 8.22 (s, 1H, adenine-H), 7.69-7.58 (m, 2H, Ar-H), 7.47-
7.37 (m, 3H, Ar-H), 7.32 (s, 2H, NH), 5.14 (d, J(P,H) = 12.0 Hz, 3H, 
OCH3), 4.54-4.49 (m, 2H, NCH2), 3.42-3.29 (m, 2H, SeCH2) ppm. 
13C NMR (DMF-d7, δ), 157.0 (adenine-C), 153.8 (adenine-C), 153.0 
(adenine-C), 141.5 (adenine-C), 139.3 (Ar-C), 133.3 (Ar-C), 130.7 
(Ar-C), 128.0 (Ar-C), 119.7 (adenine-C), 53.1 (OCH2), 43.5 (NCH2), 
31.7 (SeCH2) ppm. 
31P NMR (DMF-d7, δ), 83.6 (s, J(P,Se) = 439 Hz, 
J(P,Se) = 831 Hz) ppm. 77Se NMR (DMF-d7, δ), 307.8 (d, J(P,Se) = 
439 Hz), -105.9 (d, J(P,Se) = 830 Hz) ppm. Mass spectrum [APCI+, 
m/z]: 462 [M+H]+. Accurate mass measurement [APCI+, m/z]: 
461.9493 [M+NH4]
+, calculated mass for C14H16N5OPSe2H: 
461.9498. 
 
3.2.10.1. Se-(2-(6-Amino-9H-purin-9-yl)ethyl) O-ethyl 
phenylphosphonodiselenoate (16). 
 
    0.740 g as white solid in 78% yield. M.p. 157-159°C. Selected IR 
(KBr, cm-1): 3333.9(m), 3147(m), 1649(vs), 1596(vs), 1576(s), 
1483(s), 1437(m), 1416(m), 1354(m), 1326(m), 1309(m), 1223(s), 
1105(m), 1015(s), 943(s), 796(m), 740(m), 685(m), 645(m), 601(m), 
549(s), 493(s). 1H NMR (DMF-d7, δ), 8.05 (s, 1H, adenine-H), 7.94 
(s, 1H, adenine-H), 7.87-7.76 (m, 2H, Ar-H), 7.50-7.46 (m, 3H, Ar-
H), 7.15 (s, 2H, NH2), 4.35 (dt, J(H,H) = 6.6 Hz, J(P,H) = 1.7 Hz, 
2H, NCH2), 4.14-3.90 (m, 2H, OCH2), 3.27-3.18 (m, 2H, SeCH2), 
1.22 (t, J(H,H) = 7.0 Hz, 3H, CH3) ppm. 
13C NMR (DMF-d7, δ), 
156.9 (adenine-C), 153.2 (adenine-C), 150.4 (adenine-C), 141.2 
(adenine-C), 137.5 (Ar-C), 133.2 (Ar-C), 130.6 (Ar-C), 129.2 (Ar-
C), 119.8 (adenine-C), 63.6 (OCH2), 43.4 (NCH2), 31.7 (SeCH2), 
15.6 (CH3) ppm. 
31P NMR (DMF-d7, δ), 79.3 (s, J(P,Se) = 436 Hz, 
J(P,Se) = 826 Hz) ppm. 77Se NMR (DMF-d7, δ), 319.7 (d, J(P,Se) = 
434 Hz), -97.9 (d, J(P,Se) = 825 Hz) ppm. Mass spectrum [APCI+, 
m/z]: 476 [M+H]+. Accurate mass measurement [APCI+, m/z]: 
475.9652 [M+NH4]
+, calculated mass for C15H18N5OPSe2H: 
475.9655. 
 
 
3.2.10.1. Se-(2-(6-Amino-9H-purin-9-yl)ethyl) O-isopropyl 
phenylphosphonodiselenoate (17). 
 
    0.335 g as white solid in 69% yield. M.p. 141-142°C. Selected IR 
(KBr, cm-1): 3319(m), 3141(m), 1649(s), 1589(s), 1574(m), 
1480(m), 1416(m), 1327(m), 1305(m), 1246(m), 1225(m), 1098(s), 
962(s), 885(m), 795(m), 733(m), 687(m), 644(m), 546(s), 494(m). 
1H NMR (DMF-d7, δ), 8.38 (s, 1H, adenine-H), 8.25 (s, 1H, adenine-
H), 8.14-8.06 (m, 2H, Ar-H), 7.81-7.73 (m, 3H, Ar-H), 7.53 (s, 2H, 
NH2), 5.16-5.03 (m, 2H, OCH), 4.74-4.58 (m, 2H, NCH), 3.70-3.47 
(m, 2H, SeCH2), 1.54 (dd, J(H,H) = 6.3 Hz, J(P,H) = 1.6 Hz, 3H, 
CH3) ppm. 
13C NMR (DMF-d7, δ), 157.1 (adenine-C), 153.3 
(adenine-C), 150.5 (adenine-C), 141.7 (adenine-C), 138.3 (Ar-C), 
137.0 (Ar-C), 130.6 (Ar-C), 129.3 (Ar-C), 119.9 (adenine-C), 73.9 
(OCH), 43.5 (NCH2), 32.1 (SeCH2), 23.9 (CH3) ppm. 
31P NMR 
(DMF-d7, δ), 76.8 (s, J(P,Se) = 434 Hz, J(P,Se) = 825 Hz) ppm. 
77Se 
NMR (DMF-d7, δ), 338.6 (d, J(P,Se) = 434 Hz), -92.1 (d, J(P,Se) = 
825 Hz) ppm. Mass spectrum [ESI+, m/z]: 490 [M+H]+; 512 
[M+Na]+. Accurate mass measurement [ESI+, m/z]: 489.9800 
[M+H]+, calculated mass for C16H20N5OPSe2H: 489.9814; Accurate 
mass measurement [ESI+, m/z]: 511.9615 [M+Na]+, calculated mass 
for C16H20N5OPSe2Na: 511.9634. 
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